Okmetic Oyj - Decisions of extraordinary general meeting

DECISIONS OF THE EXTRAORDINARY GENERAL MEETING OF OKMETIC OYJ

OKMETIC OYJ   STOCK EXCHANGE RELEASE   6 NOVEMBER 2008   AT 10.30 A.M.	

DECISIONS OF THE EXTRAORDINARY GENERAL MEETING OF OKMETIC OYJ

The extraordinary general meeting of Okmetic Oyj held on 6 November 2008
decided that the number of members on the company's board of directors would be
increased to six. Henri Österlund, Managing Director of Accendo Capital
Partners Oy, was appointed as a new member of the board. The general meeting
accepted the board of directors' proposal regarding the board's authorisation
to repurchase or transfer rights to the company's own shares. 

1. Members of the board of directors

The number of members on the company's board of directors was set at six. Henri
Österlund, M.Sc. (Economics and Business Administration) was appointed as a new
member of the board. He is the Managing Director of Accendo Capital Partners
Oy. The new board member will be entitled to remuneration proportional to the
length of his term of office, calculated on the basis of the 17,400 euro which
is payable for a full term of office as per the decision of the annual general
meeting of 3 April 2008. 

Okmetic's board of directors now comprises Mikko J. Aro as chairman, Karri
Kaitue as deputy chairman, and Tapani Järvinen, Jarmo Niemi, Pekka Salmi and
Henri Österlund as members. 

2. The board of directors' authorisation to decide on repurchasing the
company's own shares 

The general meeting accepted the board of directors' proposal regarding the
board's authorisation to decide on repurchasing the company's own shares as
follows: 

The aggregate number of shares repurchased on the basis of the authorisation
cannot exceed 1,688,750 shares, which represents 10 percent of all the shares
of the company. The company and its subsidiaries together cannot at any time
own more than 10 percent of all of the company's registered shares. 

Only unrestricted shareholders' equity can be used to repurchase the company's
own shares under the authorisation. Own shares can be repurchased at a price
determined by public trading on the day of repurchase or at another
market-based price. 

The board of directors can decide the method of repurchasing the company's own
shares as well as the other terms and conditions. Derivatives, for example, can
be used in the repurchase. Shares can be repurchased independently of the
shareholders' proportional share holdings (directed repurchase). The
authorisation remains in force until the annual general meeting of spring 2010,
however, until no later than 6 May 2010. 

3. The board of directors' authorisation to decide on transferring rights to
the company's own shares 

The general meeting accepted the board of directors' proposal regarding the
board's authorisation to decide on transferring rights to the company's own
shares as follows: 

The aggregate number of rights transferred on the basis of the authorisation
cannot exceed 1,688,750 shares, which represents 10 percent of all the shares
of the company. 

The board of directors was authorised to decide on all the terms and conditions
of share issues. The authorisation will be limited to transferring rights to
the company's own shares as held by the company. The share issue can be carried
out as a directed issue. The board of directors may also decide to cancel the
repurchased shares. The authorisation will be effective until further notice,
however, until no later than 30 June 2013. Moreover, the authorisation cannot
override the authorisation granted at the annual general meeting of 3 April
2008 regarding share issues. 

OKMETIC OYJ

Antti Rasilo
President

For further information, please contact:

President Antti Rasilo, Okmetic Oyj,
tel. +358 9 5028 0232, email: antti.rasilo@okmetic.com 

Senior Vice President, Finance Esko Sipilä, Okmetic Oyj,
tel. +358 9 5028 0286, email: esko.sipila@okmetic.com

Distribution:

NASDAQ OMX Helsinki
Principal media
www.okmetic.com

OKMETIC IN BRIEF

Take it higher

Okmetic is a technology company which supplies tailor-made silicon wafers for
sensor and semiconductor industries and sells its technological expertise.
Okmetic provides its customers with solutions that boost their competitiveness
and profitability. 

Okmetic's silicon wafers are part of a further processing chain that produces
end products that improve human interaction and quality of life. Okmetic's
products are based on high-tech expertise that generates added value for
customers, innovative product development and an extremely efficient production
process. 

Okmetic has a global customer base and sales network, production plants in
Finland and the US and contract manufacturers in Japan and China. 

Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For
more information on the company, please visit our website at www.okmetic.com